AD ADMA ADMA Biologics, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Author argues ADMA's long-term growth story remains intact, with at least $530M expected 2026 revenue and a path to $1B by 2030 requiring only 17.2% annual growth, helped by ASCENIV's 31% YoY Q3 2026 growth and 2–4% monthly end-user demand growth. At a conservative 50% adjusted EBITDA margin on $1B revenue and 12–15x EV/EBITDA, the author estimates roughly $26–32 per share when those targets are achieved, while SG-001 and activist investors add optional upside. Main stated risks are that future margins, debt and dilution could change the outcome, SG-001 is early-stage, and there is no confirmed acquisition discussion.

The author believes ADMA can grow from at least $530M of expected 2026 revenue to $1B by 2030, requiring only about 17.2% annual growth. At a 50% adjusted EBITDA margin and 12-15x EV/EBITDA, the post cites an illustrative $26-32 per share value when targets are achieved, not as a current price target. SG-001, activist investor involvement, and strategic takeover appeal are optional upside, while the main stated risk is that future margins, debt, and dilution could substantially change the outcome.

The author argues the market may be underestimating ADMA's standalone earnings power as ASCENIV grows and the company could reach roughly $1 billion in revenue by 2030. At a 50% adjusted EBITDA margin and a 12–15x EV/EBITDA multiple, the post cites an illustrative enterprise value of $6–7.5 billion, or about $26–32 per share, with SG-001 providing additional long-term optionality. The main stated risks include the earlier guidance reset, the illustrative nature of the 2030 assumptions, early-stage SG-001, and no confirmed evidence of takeover negotiations.